Teva Pharma (TEVA) Investors Look To Analyst Day

December 3, 2012 11:14 AM EST
Get Alerts TEVA Hot Sheet
Price: $33.97 --0%

Rating Summary:
    19 Buy, 20 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade TEVA Now!
Join SI Premium – FREE
On Friday Teva Pharma (NYSE: TEVA) issued 2013 guidance that disappointed investors, sending shares lower. However, shares later recovered losses as investors looked past guidance and evaluated the company on a broader range of issues.

Commenting on developments, analyst Randall Stanicky of Canaccord Genuity said "With the earnings bar set low and a multi-year cost-cutting story introduced, we expect focus to shift to revenue and pipeline visibility, which we expect from the analyst day."

Analyst day is set for December 11th and could be a driver for the stock, thinks Stanicky.

Canaccord Genuity has a Buy rating on Teva with a $50 price target.

For an analyst ratings summary and ratings history on Teva Pharma (NYSE: TEVA) click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $40.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Earnings, Canaccord Genuity

Add Your Comment